Walleye Capital’s Relay Therapeutics RLAY Stock Holding History

Walleye Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100	Closed	-$1.26K	–	5254
2023 Q2	$1.26K	Buy	+100	New	+$1.24K	﹤0.01%	4187

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Capital's RLAY Position: Q2 2025 in Review

Walleye Capital sold out of Relay Therapeutics (RLAY) in Q2 2025, closing a stake of 101,548 shares — an estimated $266K sold.

Walleye Capital first reported a position in RLAY in Q3 2022 and held it in 7 quarters. The position peaked at $12.9M in Q3 2024. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

Walleye Capital reported no remaining Relay Therapeutics position as of Q2 2025 after selling out during the quarter.
Walleye Capital sold 101,548 Relay Therapeutics shares in Q2 2025, an estimated $266K.
Walleye Capital first reported a position in Relay Therapeutics in Q3 2022 and held it in 7 quarters.
Walleye Capital's Relay Therapeutics position peaked at $12.9M in Q3 2024.
208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.